A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)

NCT03150589 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

705

Enrollment

INDUSTRY

Sponsor class

Conditions

Age-Related Macular Degeneration

Interventions

DRUG: SB11 (Proposed ranibizumab biosimilar)
DRUG: Lucentis (ranibizumab)

Sponsor

Samsung Bioepis Co., Ltd.